# TRIMTECH Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trimtech-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.trimtechtherapeutics.com
- Total disclosed funding: $48M
- Latest round: Seed (Feb 5, 2026)
- Investors on record: 11

## About

Founded in 2023 in Cambridge, UK, TRIMTECH Therapeutics Limited specializes in biotherapeutics targeting protein aggregation disorders. Trimtech Therapeutics specializes in the development of a distinctive portfolio of therapeutic agents aimed at treating central nervous system (CNS) and inflammatory disorders. The company's core offerings, known as TRIMTACs™ and TRIMGLUEs™, are designed to selectively target and eliminate disease-causing protein aggregates. This innovative approach harnesses the potential of TRIM21, a ubiquitin ligase that the company has identified as an underutilized but widely expressed target in the treatment of protein aggregation disorders. The primary end-users of these therapeutic solutions are patients suffering from intractable CNS conditions and inflammatory diseases. Trimtech Therapeutics is focused on delivering its products in key global markets, including North America, Europe, and parts of Asia, thereby addressing a diverse client base that spans healthcare providers, research institutions, and pharmaceutical companies. The company's revenue structure is based on partnerships with pharmaceutical companies and research institutions, allowing for collaborative development and commercialization of its proprietary technologies. Transactions are expected to occur through B2B partnerships, wherein Trimtech collaborates with larger pharmaceutical firms to integrate its TRIMTACs™ and TRIMGLUEs™ into broader therapeutic frameworks. Revenue generation is further supported by potential licensing agreements and milestone payments tied to the development stages of its products. These agreements typically revolve around the successful advancement of therapeutic candidates through clinical trials, ultimately driving value creation for both Trimtech and its partners. In June 2026, TRIMTECH Therapeutics Limited raised EUR 12 million in seed funding co-led by Johnson & Johnson Innovation and BGF Investment Management, with participation from Cambridge Innovation Capital, Pfizer Venture Investments, Eli Lilly & Company, MP Healthcare Venture Management, M Ventures, and Cambridge Enterprise Ventures.

## Funding rounds

- Seed, Feb 5, 2026, $22M — Johnson & Johnson Innovation, Cambridge Enterprise Ventures, M Ventures, MP Healthcare Venture Management, Pfizer Venture Investments, BGF Investment Management, Eli Lilly & Company, Cambridge Innovation Capital
- Seed, Dec 3, 2024, $25M — SV Health Investors, Cambridge Enterprise, M Ventures, MP Healthcare Venture Management, Pfizer Venture Investments, Eli Lilly & Company, Cambridge Innovation Capital, Start Codon

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed
- Cambridge Enterprise — Seed
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Seed
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Seed
- Eli Lilly & Company — Seed
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Seed
- Start Codon (https://capitalatlas.ai/funds/start-codon) — Seed
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed
- Cambridge Enterprise Ventures (https://capitalatlas.ai/funds/cambridge-enterprise-ventures) — Seed
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Seed